Nextcure and collaborators publish preclinical data on novel immunomedicine nc410

Beltsville, md., june 21, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal elife establishing nc410 as a novel immunomedicine targeting immune-excluded regions of collagen-rich tumors and enabling normalization of the tumor immune microenvironment. nc410, currently being evaluated in a phase 1/2 clinical trial in patients with advanced or metastatic solid tumors, is a first-in-class immunomedicine designed to block immune suppression mediated by lair-1, an immunomodulatory receptor expressed on t cells and myeloid cells, including dendritic cells.
NXTC Ratings Summary
NXTC Quant Ranking